Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Cohen

Showing results (51-60 of 113) with videos related to

Pageof 12
Sort By:
Multiple Sclerosis and Related Disorders|April 17, 2015
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findingsLudwig Kappos, Jeffrey Cohen, William Collins, et al.
Journal of Religion and Health|April 11, 2023
Chaplaincy, Clergy, Prayer, Cancer and Measuring Religion and HealthLindsay B Carey, David Drummond, Harold G Koenig, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2014
A systematic review of the incidence and prevalence of cancer in multiple sclerosisRuth Ann Marrie, Nadia Reider, Jeffrey Cohen, et al.
Journal of Religion and Health|March 4, 2023
Pediatrics, Students, Allied Health and COVID-19Lindsay B Carey, Jeffrey Cohen, Ezra Gabbay, et al.
Bioorganic & Medicinal Chemistry Letters|February 23, 2002
Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazinesPuwen Zhang, Eugene A Terefenko, Andrew Fensome, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2005
SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonistsEugene A Terefenko, Jeffrey Kern, Andrew Fensome, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2014
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosisRuth Ann Marrie, Nadia Reider, Jeffrey Cohen, et al.
Journal of Religion and Health|September 24, 2022
Cancer, Religious Philosophy, Death and DyingLindsay B Carey, Harold G Koenig, Jeffrey Cohen, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonistsAndrew Fensome, Marci Koko, Jay Wrobel, et al.
Experimental Neurology|June 13, 2017
CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cellsAlex Sargent, Lianhua Bai, Genevieve Shano, et al.
Pageof 12

Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Multiple Sclerosis and Related Disorders|April 17, 2015
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findingsLudwig Kappos, Jeffrey Cohen, William Collins, et al.
Journal of Religion and Health|April 11, 2023
Chaplaincy, Clergy, Prayer, Cancer and Measuring Religion and HealthLindsay B Carey, David Drummond, Harold G Koenig, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2014
A systematic review of the incidence and prevalence of cancer in multiple sclerosisRuth Ann Marrie, Nadia Reider, Jeffrey Cohen, et al.
Journal of Religion and Health|March 4, 2023
Pediatrics, Students, Allied Health and COVID-19Lindsay B Carey, Jeffrey Cohen, Ezra Gabbay, et al.
Bioorganic & Medicinal Chemistry Letters|February 23, 2002
Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazinesPuwen Zhang, Eugene A Terefenko, Andrew Fensome, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2005
SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonistsEugene A Terefenko, Jeffrey Kern, Andrew Fensome, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2014
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosisRuth Ann Marrie, Nadia Reider, Jeffrey Cohen, et al.
Journal of Religion and Health|September 24, 2022
Cancer, Religious Philosophy, Death and DyingLindsay B Carey, Harold G Koenig, Jeffrey Cohen, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonistsAndrew Fensome, Marci Koko, Jay Wrobel, et al.
Experimental Neurology|June 13, 2017
CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cellsAlex Sargent, Lianhua Bai, Genevieve Shano, et al.
Pageof 12